October 4-5, 2018 | Boston, MA
Pre-Conference Workshop Days | October 2-3, 2018

Bristol-Myers Squibb

Expertise Partner

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees around the world work together for patients – it drives everything we do.



Expertise Partner

Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Driven by a passion for excellence and a relentless commitment to quality, we unlock opportunities that advance innovation and deliver on the promise of a healthier world.




Expertise Partner

ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.




Expertise Partner

Our portfolio of proprietary enabling technologies combined with our team of industry experts and scalable partnering approach, allows us to support all your needs from discovery through commercialization. We offer end-to-end, full-service solutions that include upfront discovery, assay development, clinical testing, regulatory filing, cGMP manufacturing and global product commercialization.




Expertise Partner

Siemens Healthcare Diagnostics is a global diagnostics company that 25,000+ customers in over 100 countries. We provide healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Through Siemens Clinical Laboratory, we provide companion and complimentary diagnostics test development and testing capabilities for therapy development programs.



Guardant Health

Expertise Partner

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.




Expertise Partner

MolecularMD develops and commercializes specialty diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates proven and innovative platform technologies with clinical assay design, validation, and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. MolecularMD’s core competency is in streamlining the development, regulatory approval, and clinical deployment of precision oncology medicines. The company provides customized Clinical Trial Assay and CDx development in their CAP-accredited, CLIA-certified laboratories in Portland, Oregon and Cambridge, Massachusetts.



Vortex Biosciences

Expertise Partner

The Vortex Biosciences mission is to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives.

We are in the midst of a paradigm shift in how cancer can be diagnosed and treated. The combination of targeted therapies and precise diagnostics is allowing for the era of personalized medicine to emerge. The capture and enrichment of circulating tumor cells is going to be a critical element of targeted companion diagnostics. We believe our next generation CTC capture system will allow the full diagnostic potential of CTCs to finally be realized.



Expertise Partner

NanoString Technologies is a provider of life science tools for translational research and developer of molecular diagnostic products. The company’s nCounter® Analysis System delivers highly-multiplexed, direct profiling of individual molecules in a single reaction without amplification. Applications include Gene Expression, Single-Cell, miRNA and CNV.




Almac Diagnostics

Program Partner

Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories, based in the UK and US offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.




Program Partner

NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.



Personal Genome Diagnostics

Program Partner

Personal Genome Diagnostics (PGDx) advances the frontiers of cancer medicine through innovative genomic technologies for oncology researchers, drug developers, clinicians and patients. The expert team at PGDx draws on a deep understanding of cancer biology and extensive experience in cancer genomics and clinical oncology to pioneer genomic methods. These novel technologies precisely identify and characterize unique genomic alterations in tumors.



Sysmex Inostics

Program Partner

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a leader in blood-based molecular diagnostics testing in oncology.  Our highly sensitive OncoBEAM™ kits and tests offer a minimally-invasive alternative for the detection of cancer gene mutations, clinical trials testing and companion diagnostics development.



Program Partner

Along with Roche Pharamceuticals, Roche Diagnostics is an important part of the foundation that modern healthcare builds upon. Our broad range of innovative diagnostics tests and systems play a pivotal role in the ground-breaking area of integrated healthcare solutions and cover the early detection, targeted screening, evaluation and monitoring of disease. Roche Diagnostics is active in all market segments, from scientific research and clinical laboratory systems to patient self-monitoring.



Leica Biosystems 

Program Partner

Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

In line with our Mission, we have established the following challenge for ourselves: Enable patients to get their diagnosis within 24 hours from biopsy. This is a goal we are striving towards, a goal that will guide our future strategies. This vision aims to decrease the time it takes from biopsy to patient diagnosis, to a 24 hour period. With a presence in every step of the workflow, no other company is positioned to streamline all these steps so that the whole process takes less than 24 hours.



Quest Diagnostics

Panel Partner

Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.




Program Partner

Corgenix is a global diagnostics company that commercializes Immunoassay IVDs for autoimmune, cardiovascular and liver diseases. Additionally, Corgenix has more than 20 years’ experience in contract Immunoassay development and manufacturing, serving the needs of Pharma and Diagnostic companies. Our Personalized Diagnostics Team collaborates with Pharma and other Personalized Medicine stakeholders to develop and commercialize companion diagnostics. Our newly established CLIA laboratory allows for better management of the assay development process and provides more options for our Partners.



Thermo Fisher Scientific Inc.

Program Partner

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.


Horizon Diagnostics

Program Partner

Horizon Diagnostics, a business unit of Horizon Discovery Group plc, is a leading provider of genetically defined, human genomic reference standards, including FFPE cell line sections and purified genomic DNA. HDx™ Reference Standards offer a sustainable source of reference material to laboratories, proficiency schemes and manufacturers, providing an unprecedented level of control.



Agilent Technologies

Program Partner

Diagnostic certainty for every patient is a critical first step in the fight against cancer. Agilent’s Dako pathology solutions are designed to help hospitals and pathology laboratories around the world make fast and accurate diagnoses. This enables the most effective treatment decisions for cancer patients, ultimately improving patient care and enhancing survival rates.




Program Partner

Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.



Program Partner

QIAGEN serves more than 500,000 customers around the globe, all seeking insights from the building blocks of life – DNA, RNA and proteins. We deliver Sample to Insight solutions for molecular testing, propelling QIAGEN customers from start to finish to unlock new insights. This is how we make improvements in life possible.



Program Partner

As an expert in immune biomarkers, HalioDx goal is to play a leading role in partnering with academic and pharmaceutical industry to leverage the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients.

By precisely measuring the immune reaction in and around the tumor, HalioDx first tests already allow clinicians to determine the degree of severity of a patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.



Program Partner




Spotlight Partner

Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options. The company is launching products and services that seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.




Spotlight Partner

Cofactor Genomics, Inc. is a translational and clinical assay company using RNA as the foundation for providing a better understanding of disease. We’ve invested in the development of proprietary databases focused on (1) cancer-specific gene expression and (2) unique immune cell RNA expression fingerprints. These databases enable us to quantify complex molecular profiles, and provide comprehensive characterization of immune response in all solid tumor tissues. Cofactor leverages our expertise in high-throughput sequencing, CAP-accredited laboratory, and unique machine-learning algorithms to deliver candidate biomarkers in an easy-to-interpret report.




Panel Partner

We improve patient lives by unlocking the tissue phenome. Our work model builds on a simple premise: Tissue Phenomics strengthens results, from biomarker discovery to clinical development and meaningful diagnostics. We bring Tissue Phenomics to you, seamlessly integrate into your processes, and act as your reliable, science-driven partner along the way.




Spotlight Partner

DxTerity is a patient-centric genomics company bringing the power of real-world genomics with from-home RNA monitoring to the management of immune-mediated disease. With patented and proprietary technologies that engage patients where they live by stabilizing RNA at ambient temperature, DxTerity is increasing clinical study efficiency while transforming the management of immune-mediated disease by helping to provide a more complete picture of an individual’s health. We unite patients, providers, advocacy groups and researchers in a common mission to improve healthcare and enable patients to live life confidently.



Flagship Biosciences

Spotlight Partner

Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions.

With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to:

  • Make informed pipeline decisions that will accelerate the right clinical path
  • Enable critical go/no go decisions based on confirmation of action
  • Design, implement and evaluate prototype diagnostic strategies
  • Differentiate commercial strategies to increase probability of success

Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship’s technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.



Spotlight Partner

Unilabs is a leader in Companion Diagnostic testing in Europe with several years of experience with the associated necessary global, customized logistics & regulatory know-how.

Unilabs is Serving Pharma as a highly customer centric and specialized bioanalytical laboratory service partner with structured processes to reduce budget risks & stalling of drug development.

Unilabs has more than 8.000 employees, and more than 30 years of clinical trials experience, handling more than 3.000 studies involving a broad range of matrices from numerous species and in a vast number of therapeutic areas.




Panel Partner

Evidera provides evidence, value, and insight through health economics, outcomes research, market access, data analytics and epidemiology offerings. We partner with life sciences organizations worldwide to optimize the market access and commercial success of their products by leveraging our unparalleled knowledge of the global payer and regulator landscape. Our research and consulting services are driven by world-class science and thought leadership to address the changing healthcare landscape, including solutions for precision and transformative technologies.


   ClearView Healthcare Partners

Panel Partner

Founded in 2007, ClearView Healthcare Partners is a global strategy consulting firm serving the life sciences sector. The firm combines global industry knowledge and deep scientific expertise across a range of therapeutic areas with an extensive network of external stakeholders to deliver practical and actionable recommendations to our clients’ most complex challenges. The firm’s projects include cross-functional support at the corporate, franchise, and product levels for pharmaceutical, biotech, medtech, and diagnostics companies worldwide.



Panel Partner

Diaceutics is the diagnostic development and commercialization service provider. We have been leading this field for 13 years, entirely focused on the intersection between diagnostics and therapeutic decision making. We provide an end to end service that encompasses everything from understanding the diagnostic landscape to test implementation in treatment pathways. This is all enabled by a robust flow of data from our global laboratory network. Our ultimate goal is to drive better testing to enable better treatment decisions for patients.



Randox Laboratories

Spotlight Partner

Randox Biosciences are a highly innovative global leader in clinical diagnostic manufacturing supplying the world’s top CRO’s and biopharmaceutical companies. We have technical expertise in diagnostic and CDx assay development utilising single analyte assays, as well as multiplex assays that test up to 23 biomarkers using one patient sample via our Evidence range of analysers. This utilises our proprietary Biochip Array Technology which was developed using our in house range of antibodies, proteins and conjugates. We also offer a custom development service for all our raw materials for the biopharmaceutical and diagnostic industries. As well as custom assay development, our custom services also include polyclonal and monoclonal development and recombinant antibody fragments (sdAb, scFv, Fab).



Spotlight Partner

Here at Calico Biolabs, we partner with diagnostic and pharmaceutical companies, both large and small, to develop custom rabbit monoclonal antibodies. With the annual incidence of new cancer cases predicted to surpass 23 million by the year 2030, the need for personalized medicine is more important than ever. ​​We are dedicated to creating a variety of products that approach this growing problem in two different ways – via medical research and companion diagnostics.




Spotlight Partner

Enabling higher multiplexing for real-time PCR instruments. Leveraging digital signal processing to provide higher efficiency and lower costs for our laboratory customers. ChromaCode is deploying a disruptive solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​ , exclusively licensed from the California Institute of Technology.


CDI Laboratories

Spotlight Partner

CDI, the result of intensive efforts and advances developed by the High-Throughput Biology Center at Johns Hopkins University, is a privately owned research and discovery company in the field of proteomics. The company was created by scientists for scientists, addressing the critical needs required in order to accelerate research, advance discoveries and translate these discoveries into novel products and services that improve human health.The company applies its accelerating platforms to internal, collaborative, and client programs.




Spotlight Partner

AroCell has developed the AroCell TK 210 ELISA – a novel, improved assay for the well-known cell-proliferation biomarker, Thymidine Kinase 1 (TK1). In drug discovery and development, the AroCell TK 210 ELISA can be used to stratify subjects, aid in making prognoses and monitoring therapy response. Furthermore, the AroCell TK 210 ELISA can be applied to in-vitro and xenograft samples making it a translational biomarker. Being based on a standard ELISA format the AroCell TK 210 can easily and profitably be combined with other biomarkers.




Meeting Partner

ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.




Q2 Solutions

Exhibition partner

Q2 Solutions is a leading global clinical trials laboratory services organization that partners with biopharmaceutical, medical device and diagnostics customers to transform science and data into actionable medical insights. Its laboratory services span the development lifecycle from Discovery through Clinical Trials to Commercialization that includes predictive biomarker solutions for Companion Diagnostics.





Precision for Medicine

Exhibition Partner

At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team ofexperts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhancepatient outcomes, and realize the full commercial potential of new therapies and products.




Exhibition Partner

Insights from biomedical big data. Intomics is specialized in deriving core biological insights form analysis and integration of biomedical big data. By applying our sophisticated technology and integrating different biomedical datasets we increase the success rate of drug discovery and development projects for clients in the pharmaceutical industry.



Meeting Partner

Invivoscribe is the worldwide leader in precision medicine and companion diagnostics (CDx) for hematological malignancies. Invivoscribe offers a full range of hematology-oncology testing products and services (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software), all developed under ISO 13485 design control and manufactured in our own cGMP facility. We also operate the Laboratories for Personalized Molecular Medicine (LabPMM), a global network of clinical reference labs with locations in the United States, Germany, and Japan. These laboratories offer an ever-expanding menu of internationally harmonized tests to support the stratification and enrollment of patients in clinical trials, optimized treatments, and development of CDx. We continually strive to provide access to accurate test results and improve the quality of healthcare worldwide


Olink Proteomics

Roundtable Partner

Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics provides outstanding products and services for targeted human protein biomarker discovery. We help scientists get answers quickly and confidently through robust, multiplex biomarker analysis. Olink immunoassay panels enable rapid, high-throughput analysis, with exceptional data quality and minimal sample consumption. Using just 1 µl of sample, 92 biomarkers are assayed simultaneously, with up to 96 samples run per panel. Our Proximity Extension Assay (PEA) technology enables this high level of multiplexing, as this dual recognition, DNA-coupled method provides exceptional readout specificity. Disease area or biological process-focused panels have both validated and exploratory biomarkers, and our rigorous assay validation data is freely available. Choosing either ready-to-use kits or our Analysis Service, customers get high quality data and rapid high-throughput analysis that makes the most effective use of their precious samples.


For further information please don’t hesitate to send us an email.